mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

Summary

This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and sintilimab. The purpose of this trial is to evaluate the efficacy and safety of this treatment regimen and to preliminarily explore the correlation between biomarkers and treatment outcomes.

Timeline

Start

2024-12-23

Primary completion

2027-03

Completion

2027-05

Drugs

Indications